Donor-derived fecal microbiota treatments are efficacious in preventing recurrent Clostridioides difficile infection (rCDI), but they have inherently variable quality attributes, are difficult to scale and harbor the risk of pathogen transfer. In contrast, VE303 is a defined consortium of eight puri …

Diarrhea associated with enteric infections, gut inflammation, and genetic defects poses a major health burden and results in significant morbidity and mortality. Impaired fluid and electrolyte absorption and/or secretion in the intestine are the hallmark of diarrhea. Electroneutral NaCl absorption …

Clostridioides difficile is the leading cause of healthcare- and antibiotic-associated diarrhea. Surface layer protein A (SlpA), an essential component of the bacterium's outermost layer, contributes to colonization and inflammation. The peroxisome proliferator-activated receptor gamma (PPAR-γ) has …

Clostridioides difficile (C. difficile) infection (CDI) is a life-threatening healthcare-associated infection occurring worldwide. C. difficile toxins (toxin A and toxin B) are the major virulence factors, causing CDI-related diarrhea and complications. Recent studies have shown that sulfated glycos …

Xeno Biosciences may have been unable to prove that its drug delivering oxygen to the gastrointestinal tract can induce weight loss, but LPOXY Therapeutics has penned a

Background: Clostridioides difficile (C. difficile) infection (CDI) is the primary cause of antibioticassociated diarrhea. Due to its high resistance rate to...

/PRNewswire/ -- LPOXY Therapeutics, Inc. ("LPOXY"), a clinical-stage biopharmaceutical company focused on innovative therapies for infectious disease...

Nature Medicine - Results of multi-omic profiling of the microbiome and host immunity of individuals treated with VE303 to prevent recurrent Clostridioides difficile infection in the context of a...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in Phase 2. Data expected in 2025.

Joseph Zackular, PhD suggests that mRNA vaccines and monoclonal antibodies could offer more effective treatments for recurrent C difficile infections

Pfizer Pflash: A Spotlight on Clostridioides difficile Vaccine Development Presentation intended for 1 ...

Vedanta Biosciences offered further insights on its completed phase 2 trial for its novel therapeutic, VE303.

Joseph Zackular, PhD, shares insights on his team’s mRNA vaccine research for C difficile, highlighting progress in animal models and future plans for human trials.

Clostridioides difficile is a major cause of nosocomial infections, often associated with individuals who have gut dysbiosis from previous antibiotic therapies. C. difficile infections (CDI) have a high recurrence rate and impose significant financial and mortality burdens on the healthcare system. …

Based on our findings, we elucidate a novel mechanism by which PAMK alleviates DSS-induced colitis and thus provides evidence to support the potential development of PAMK as a new clinical drug against UC.

To investigate whether the polysaccharide component of the Traditional Chinese Medicine (TCM) formula Lizhong decoction (LZD) has therapeutic effects and regulates gut microbiota in antibiotic-associated diarrhea (AAD) related to Clostridium difficile infection, a polysaccharide was extracted from L …

Acurx Pharmaceuticals (ACXP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on December 10. Analyst Ed...

Acurx prepares for Phase 3 trials in C. difficile treatment

Clostridioides difficile is a gram-positive bacteria that causes disease in persons with dysbiosis of the gut microbiota and has been listed as an urgent threat due to the emergence of resistance.

Enteric pathogens are studied and antigens identified, which can be designed, synthesized, and cloned into expression genetic vectors and used to transform plants through physical, chemical, and biol...

Albany United States As per DelveInsight s assessment globally Clostridium Difficile Infections pipeline constitutes 20 key companies continuously working towards developing 22 Clostridium Difficile Infections treatment therapies analysis of Clinical Trials Therapies Mechanism of Action Route of Administration and Developments ...

Researchers in the USA investigated an mRNA-lipid nanoparticle (LNP) vaccine platform to prevent Clostridioides difficile infection and disease. The vaccine constructs contained TcdA, TcdB, and PPEP-1 sequences that were well conserved across genetically diverse strains of C difficile. In mice, a bivalent (TcdA–TcdB) or trivalent (TcdA–TcdB–PPEP-1) vaccine elicited IgG responses that were two to four times higher than those elicited by a trivalent recombinant protein vaccine with alum adjuvant. All mice immunised with monovalent TcdA or TcdB mRNA-LNP vaccines survived lethal challenge with C difficile toxins, whereas those vaccinated with recombinant TcdA or TcdB died within 1 day of challenge.

Clostridioides difficile infection (CDI) recurs in one of five patients. Monoclonal antibodies targeting the virulence factor TcdB reduce disease recurrence, suggesting that an inadequate anti-TcdB response to CDI leads to recurrence. In patients with CDI, we discovered that IL-33 measured at diagno …

Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, has announced it has secured £1 million in grant funding from PACE (Pathways to Antimicrobial Clinical Efficacy).

Peripheral modification is often the main approach to optimize natural products for improved biological activity or desired physicochemical properties. This procedure inevitably increases molecular weight, often accompanied by undesired increased lipophilicity. Removing structural elements from natu …

Delivering drugs to gut tumors can be tricky. Researchers at Washington University in St. | Delivering drugs to gut tumors can be tricky. Researchers at Washington University in St. Louis have engineered an oral probiotic yeast to do the work for them, with the fungal cells able to release immune checkpoint inhibitors that shrank intestinal tumors in mice with colorectal cancer.

Patients in British hospitals with serious, antibiotic-resistant gut infections have little in common with snakebite victims overseas. But when scientists made an unlikely connection in 2018, it led to trials for a potential new treatment for antibiotic-resistant infections. In this …

Vaginal microbiome specialist Freya Bioscience ApS has added $11.8 million to its series A, bringing the total for the round to $50 million. Of the additional $11.8 million, $10.4 million comes from the Gates Foundation and is designated for the development of vaginal microbiome-based immunotherapies for treating bacterial vaginosis, a cause of preterm birth and other pregnancy complications.